Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s seizure syndrome and seizure type. The epilepsy market is highly generic, although some branded third-generation antiepileptic drugs (AEDs) have garnered notable patient share. While a few sponsors continue to follow the traditional path for drug approval in epilepsy, most drug developers are targeting underserved, orphan pediatric epilepsy indications or are developing novel formulations of rescue therapies for acute repetitive seizures. Understanding the trajectory of this established but evolving market and the niche opportunities therein is key for marketers of both current and emerging brands.

Questions Answered:

  • What is the current state of treatment in epilepsy across the G7, and what needs are left unfulfilled by approved AEDs?
  • What are the market opportunities and sales potential for agents targeting orphan epilepsy subpopulations (e.g., Epidiolex, ZX-008)?
  • What clinical role will acute intranasal rescue therapies (e.g., NRL-01, USL-261) play in the epilepsy market?
  • How will neurologists differentiate among current and emerging third-generation AEDs, and which of these agents will enjoy the greatest clinical and commercial success in the face of strong generics competition from first- and second-generation AEDs?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Approximately 20 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence of epilepsy by country, segmented by generalized and partial-onset seizures; drug-treated cases.

Emerging therapies: Phase II: 10 drugs; Phase III: 6 drugs; preregistration: 2 drugs; registered: 38 drugs. Coverage of 11 select preclinical and Phase I products.

Market forecast features: Patient-based market forecast extending through 2027.

Key companies: Aquestive Therapeutics, Eisai, GlaxoSmithKline, GW Pharmaceuticals, Insys Therapeutics, Lundbeck, Marinus Pharmaceuticals, Neurelis, Pfizer, Sanofi, SK Biopharmaceuticals, Sunovion, Supernus, UCB, Upsher-Smith, Zogenix.

Key drugs: levetiracetam, lamotrigine, carbamazepine, valproates, Vimpat (lacosamide), Aptiom/Zebinix (eslicarbazepine acetate), Fycompa (perampanel), Briviact (brivaracetam), AQST-120 (clobazam oral film), Epidiolex (plant-derived CBD), synthetic CBD, ZX-008 (fenfluramine), YKP-3089 (cenobamate), AQST-203 (buccal diazepam), NRL-1 (intranasal diazepam), USL-261 (intranasal midazolam).

Related Reports

Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogen...

View Details

Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2020

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a...

View Details

Epilepsy - Access & Reimbursement - Detailed, Expanded Analysis (US)

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and se...

View Details